Regeneron Provides Update on Biologics License Application for Linvoseltamab

1 week ago

Add Comment

by David Miller

945 Views

Written by David Miller

TARRYTOWN, N.Y., Aug. 20, 2024 (GLOBE NEWSWIRE) — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

You may also like

About the author

David Miller

Leave a Comment X

Don`t Leave Yet!